Sep 18, 2019 - The company's flagship drug is finally getting enough traction to drive major margin improvements.
Sep 18, 2019 - Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
Sep 13, 2019 - BMO Capital Markets issues rating change for INCY
Sep 11, 2019 - BMO Capital Markets issues rating change for INCY
Sep 05, 2019 - Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
Sep 05, 2019 - Oppenheimer issues rating change for INCY
Jun 13, 2019 - Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Jun 06, 2019 - Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
Jun 05, 2019 - Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.